Omiics ApS

Their core work

Omiics ApS is a Danish biotech SME based in Aarhus that works at the intersection of molecular biology, omics technologies, and neuroscience. Their project portfolio shows two distinct but complementary contributions: structural biology of disease-causing proteins (tau aggregation in Alzheimer's and tauopathies, using NMR spectroscopy and cryo-EM) and synthetic biology engineering of living cell computing systems designed to detect and suppress neurological events such as epileptic seizures. As a small company embedded in competitive EU research consortia, they most likely provide specialist experimental or analytical services — whether omics profiling, protein characterisation, or biomarker validation — that academic-led consortia need but cannot house internally. Their name ("Omiics") signals a deliberate positioning around multi-omics data generation and interpretation as a commercial offering.

What they specialise in

How they've shifted over time

Omiics entered H2020 through InterTAU with a grounding in classical structural biology — NMR spectroscopy, cryo-EM, and protein-protein interaction mapping applied to tau as a disease target. Their subsequent involvement in PRIME marks a clear step toward active intervention: instead of characterising pathology, they are now participating in engineering living cellular systems that sense and correct it. This trajectory — from observing molecular disease mechanisms to building synthetic biological circuits that respond to them — suggests Omiics is deliberately repositioning from pure analytics toward therapeutic bioengineering, tracking a broader industry shift from diagnostics to programmable medicine.

Omiics is moving from characterising neurological disease at the molecular level toward engineering autonomous biological systems that can detect and treat it — a trajectory aligned with the programmable medicine and synthetic biology space expected to attract significant EU Horizon Europe funding.

How they like to work

Omiics has participated exclusively as a consortium partner, never as coordinator, across both H2020 projects — indicating a specialist contributor model where they bring focused technical capabilities rather than project management or consortium leadership. Despite only two projects, they have engaged with 18 distinct partners across 13 countries, which is unusually broad for a small SME and suggests they are genuinely embedded in international research networks rather than orbiting a single academic host. This breadth points to a company that actively markets its services to multiple consortia rather than relying on a single long-term institutional relationship.

With 18 unique consortium partners spread across 13 countries from just two projects, Omiics has an exceptionally wide European reach for its size. Their participation in both an MSCA-RISE (mobility-focused) and a FET-RIA (frontier research) project suggests they connect to both academic mobility networks and deep-tech research communities simultaneously.

What sets them apart

Omiics occupies a rare niche as a private SME operating inside frontier EU research (FET pillar) — most companies at this level are either large pharma or spin-outs still embedded in universities. Their combination of structural biology depth (NMR, cryo-EM) and emerging synthetic biology engagement means they can speak credibly to both discovery-phase academic teams and translational biotech developers. For a consortium builder, they offer the commercial flexibility and IP agility of an SME with the scientific credibility of an organisation selected for competitive FET and MSCA funding.

Highlights from their portfolio

• PRIME
  The most ambitious project in Omiics' portfolio — engineering a personalised living cell synthetic computing circuit that autonomously senses and suppresses seizures, receiving EUR 476,875 in EC funding under the RIA scheme, with direct application to epilepsy and neurodegenerative disease treatment.
• InterTAU
  An MSCA-RISE project targeting tau protein — one of the most clinically validated but structurally elusive Alzheimer's targets — using integrative structural biology (solid-state NMR, solution NMR, cryo-EM), placing Omiics in the company of leading structural biology groups across Europe.